Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$84.12
0.911.09%
al cierre: -
$84.06
-0.06-0.07%
After hour: Aug 29, 7:34 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Merck & Co Inc ha un obiettivo di prezzo di consenso pari a $118.52, stabilito in base alle ultime valutazioni degli analisti di 28. Le ultime 3 valutazioni degli analisti sono state rilasciate da Wells Fargo, Morgan Stanley y Citigroup il julio 30, 2025, julio 10, 2025 y mayo 14, 2025. Con un obiettivo di prezzo medio di $90.67 tra le Wells Fargo, Morgan Stanley y Citigroup, c'è un implicito 7.86% upside per Merck & Co Inc da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
Wells Fargo
Morgan Stanley
Citigroup
Cantor Fitzgerald
Guggenheim
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Merck & Co
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
07/30/2025 | 7.07% | Wells Fargo | $97 → $90 | Maintains | Equal-Weight | |||
07/10/2025 | 16.58% | Morgan Stanley | $99 → $98 | Maintains | Equal-Weight | |||
05/14/2025 | -0.07% | Citigroup | $115 → $84 | Downgrade | Buy → Neutral | |||
04/22/2025 | 1.12% | Cantor Fitzgerald | → $85 | Initiates | → Neutral | |||
04/17/2025 | 36.81% | Guggenheim | $115 → $115 | Reiterates | Buy → Buy | |||
02/18/2025 | 24.91% | Deutsche Bank | $128 → $105 | Downgrade | Buy → Hold | |||
02/12/2025 | 36.81% | Guggenheim | $122 → $115 | Maintains | Buy | |||
02/05/2025 | 33.24% | B of A Securities | $118 → $112 | Maintains | Buy | |||
02/05/2025 | 14.2% | BMO Capital | $105 → $96 | Maintains | Market Perform | |||
02/05/2025 | 36.81% | Citigroup | $125 → $115 | Maintains | Buy | |||
02/05/2025 | 26.1% | Morgan Stanley | $113 → $106 | Maintains | Equal-Weight | |||
01/28/2025 | 48.7% | Citigroup | $130 → $125 | Maintains | Buy | |||
01/21/2025 | 34.43% | Morgan Stanley | $123 → $113 | Maintains | Equal-Weight | |||
01/17/2025 | 45.13% | Guggenheim | $130 → $122 | Maintains | Buy | |||
01/13/2025 | 41.57% | Leerink Partners | $136 → $119 | Maintains | Outperform | |||
01/08/2025 | 42.76% | UBS | $125 → $120 | Maintains | Buy | |||
01/08/2025 | 30.86% | Truist Securities | $130 → $110 | Downgrade | Buy → Hold | |||
12/20/2024 | 24.91% | BMO Capital | $136 → $105 | Downgrade | Outperform → Market Perform | |||
12/10/2024 | 43.94% | B of A Securities | → $121 | Reinstates | → Buy | |||
11/15/2024 | — | Wolfe Research | — | Initiates | → Peer Perform | |||
11/07/2024 | 54.65% | Truist Securities | $132 → $130 | Maintains | Buy | |||
11/06/2024 | 54.65% | Guggenheim | $137 → $130 | Maintains | Buy | |||
11/01/2024 | 30.86% | Wells Fargo | $125 → $110 | Maintains | Equal-Weight | |||
11/01/2024 | 61.79% | BMO Capital | $150 → $136 | Maintains | Outperform | |||
11/01/2024 | 46.32% | Morgan Stanley | $130 → $123 | Maintains | Equal-Weight | |||
10/25/2024 | 54.65% | Citigroup | $140 → $130 | Maintains | Buy | |||
10/17/2024 | 36.81% | Bernstein | — | → $115 | Initiates | → Market Perform | ||
10/09/2024 | 61.79% | UBS | $142 → $136 | Maintains | Buy | |||
10/09/2024 | 57.03% | Truist Securities | $143 → $132 | Maintains | Buy | |||
10/07/2024 | 66.55% | Barclays | $142 → $140 | Maintains | Overweight | |||
10/03/2024 | 84.39% | Cantor Fitzgerald | $155 → $155 | Reiterates | Overweight → Overweight | |||
09/16/2024 | 84.39% | Cantor Fitzgerald | $155 → $155 | Reiterates | Overweight → Overweight | |||
08/29/2024 | 84.39% | Cantor Fitzgerald | $155 → $155 | Reiterates | Overweight → Overweight | |||
07/31/2024 | 68.93% | Barclays | $145 → $142 | Maintains | Overweight | |||
07/31/2024 | 72.5% | B of A Securities | $150 → $145 | Maintains | Buy | |||
07/31/2024 | 48.7% | Wells Fargo | $140 → $125 | Maintains | Equal-Weight | |||
07/31/2024 | 68.93% | UBS | $148 → $142 | Maintains | Buy | |||
07/11/2024 | 59.41% | Morgan Stanley | $132 → $134 | Maintains | Equal-Weight | |||
06/20/2024 | 84.39% | Cantor Fitzgerald | $155 → $155 | Reiterates | Overweight → Overweight | |||
06/18/2024 | 84.39% | Cantor Fitzgerald | $155 → $155 | Reiterates | Overweight → Overweight | |||
06/04/2024 | 84.39% | Cantor Fitzgerald | $155 → $155 | Reiterates | Overweight → Overweight | |||
04/26/2024 | 70.12% | Truist Securities | $142 → $143 | Maintains | Buy | |||
04/18/2024 | 60.6% | Cantor Fitzgerald | $135 → $135 | Reiterates | Overweight → Overweight | |||
04/08/2024 | 70.12% | Berenberg | $140 → $143 | Maintains | Buy | |||
04/05/2024 | 60.6% | Cantor Fitzgerald | $135 → $135 | Reiterates | Overweight → Overweight | |||
04/01/2024 | 60.6% | Cantor Fitzgerald | $135 → $135 | Reiterates | Overweight → Overweight | |||
03/28/2024 | 68.93% | Truist Securities | $139 → $142 | Reiterates | Buy → Buy | |||
03/27/2024 | 60.6% | Cantor Fitzgerald | $135 → $135 | Reiterates | Overweight → Overweight | |||
03/27/2024 | 60.6% | Wells Fargo | $130 → $135 | Maintains | Equal-Weight | |||
03/11/2024 | 60.6% | Cantor Fitzgerald | $135 → $135 | Reiterates | Overweight → Overweight | |||
03/11/2024 | 23.72% | Societe Generale | → $104 | Downgrade | Hold → Sell | |||
02/29/2024 | 60.6% | Cantor Fitzgerald | $135 → $135 | Reiterates | Overweight → Overweight | |||
02/14/2024 | 60.6% | Cantor Fitzgerald | $135 → $135 | Reiterates | Overweight → Overweight | |||
02/05/2024 | 60.6% | Cantor Fitzgerald | $135 → $135 | Reiterates | Overweight → Overweight | |||
02/02/2024 | 65.36% | Truist Securities | $122 → $139 | Maintains | Buy | |||
02/02/2024 | 76.06% | UBS | $135 → $148 | Maintains | Buy | |||
02/02/2024 | 54.65% | Wells Fargo | $125 → $130 | Maintains | Equal-Weight | |||
02/02/2024 | 72.5% | Barclays | $135 → $145 | Maintains | Overweight | |||
01/23/2024 | 60.6% | Barclays | $130 → $135 | Maintains | Overweight | |||
01/09/2024 | 60.6% | Cantor Fitzgerald | $135 → $135 | Reiterates | Overweight → Overweight | |||
01/04/2024 | 60.6% | TD Cowen | $125 → $135 | Upgrade | Market Perform → Outperform | |||
11/29/2023 | 60.6% | Cantor Fitzgerald | → $135 | Reiterates | Overweight → Overweight | |||
11/20/2023 | 60.6% | Cantor Fitzgerald | → $135 | Reiterates | Overweight → Overweight | |||
11/15/2023 | 60.6% | Cantor Fitzgerald | → $135 | Reiterates | Overweight → Overweight | |||
11/09/2023 | 36.81% | Deutsche Bank | → $115 | Initiates | → Buy | |||
10/27/2023 | 40.38% | Morgan Stanley | $115 → $118 | Maintains | Equal-Weight | |||
10/27/2023 | 57.03% | BMO Capital | → $132 | Upgrade | Market Perform → Outperform | |||
10/23/2023 | 60.6% | Cantor Fitzgerald | → $135 | Reiterates | Overweight → Overweight | |||
10/11/2023 | 36.81% | Morgan Stanley | $116 → $115 | Maintains | Equal-Weight | |||
10/06/2023 | 45.13% | Truist Securities | → $122 | Reiterates | Buy → Buy | |||
10/04/2023 | 60.6% | Cantor Fitzgerald | → $135 | Reiterates | Overweight → Overweight | |||
10/02/2023 | 60.6% | Cantor Fitzgerald | → $135 | Reiterates | Overweight → Overweight | |||
09/05/2023 | 60.6% | Cantor Fitzgerald | → $135 | Reiterates | Overweight → Overweight | |||
08/22/2023 | 60.6% | Cantor Fitzgerald | → $135 | Reiterates | Overweight → Overweight | |||
08/02/2023 | 45.13% | Truist Securities | $116 → $122 | Maintains | Buy | |||
08/02/2023 | 38% | Morgan Stanley | $109 → $116 | Maintains | Equal-Weight | |||
07/20/2023 | 38% | Truist Securities | $118 → $116 | Maintains | Buy | |||
07/14/2023 | 46.32% | HSBC | → $123 | Initiates | → Hold | |||
07/11/2023 | 29.67% | Morgan Stanley | $109 → $109 | Reiterates | Equal-Weight → Equal-Weight | |||
05/30/2023 | 60.6% | Cantor Fitzgerald | → $135 | Reiterates | Overweight → Overweight | |||
05/01/2023 | 53.46% | Atlantic Equities | $127 → $129 | Maintains | Overweight | |||
05/01/2023 | 54.65% | Barclays | $128 → $130 | Maintains | Overweight | |||
04/13/2023 | 54.65% | Citigroup | $105 → $130 | Upgrade | Neutral → Buy | |||
04/11/2023 | 47.51% | Guggenheim | $123 → $124 | Maintains | Buy | |||
04/10/2023 | 54.65% | Mizuho | → $130 | Reiterates | → Buy | |||
03/17/2023 | 54.65% | Mizuho | → $130 | Reiterates | → Buy | |||
03/13/2023 | 36.81% | Wells Fargo | $120 → $115 | Downgrade | Overweight → Equal-Weight | |||
03/10/2023 | 54.65% | Berenberg | $125 → $130 | Maintains | Buy | |||
03/07/2023 | 49.89% | Credit Suisse | $125 → $126 | Maintains | Outperform | |||
03/07/2023 | 51.08% | Atlantic Equities | $122 → $127 | Maintains | Overweight | |||
03/06/2023 | 48.7% | Jefferies | → $125 | Initiates | → Buy | |||
02/23/2023 | 48.7% | JP Morgan | $120 → $125 | Maintains | Overweight | |||
02/22/2023 | 51.08% | Wolfe Research | → $127 | Upgrade | Peer Perform → Outperform | |||
02/13/2023 | 48.7% | Credit Suisse | $120 → $125 | Maintains | Outperform | |||
02/03/2023 | 42.76% | Wells Fargo | $125 → $120 | Maintains | Overweight | |||
02/03/2023 | 17.77% | Morgan Stanley | $100 → $99 | Maintains | Equal-Weight | |||
02/03/2023 | 40.38% | Truist Securities | $106 → $118 | Maintains | Buy | |||
02/03/2023 | 45.13% | SVB Leerink | $120 → $122 | Maintains | Outperform | |||
01/23/2023 | 42.76% | SVB Leerink | $112 → $120 | Maintains | Outperform | |||
01/04/2023 | 54.65% | B of A Securities | $110 → $130 | Upgrade | Neutral → Buy |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Merck & Co (MRK)?
El último precio objetivo de Merck & Co (NYSE:MRK) fue comunicado por Wells Fargo el julio 30, 2025. La firma de analistas fijó un precio objetivo para $90.00 que espera MRK a rise dentro de 12 meses (un posible 7.07% upside). 32 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Merck & Co (MRK)?
La última calificación de analistas para Merck & Co (NYSE:MRK) fue proporcionada por Wells Fargo, y Merck & Co mantuvo su equal-weight calificación.
¿Cuándo se produjo la última revisión al alza de Merck & Co (MRK)?
La última revisión al alza de Merck & Co Inc se produjo en enero 4, 2024, cuando TD Cowen elevó su precio objetivo a $135. TD Cowen anteriormente tenía a market perform para Merck & Co Inc.
¿Cuándo fue la última revisión a la baja de Merck & Co (MRK)?
La última revisión a la baja de Merck & Co Inc se produjo en mayo 14, 2025, cuando Citigroup cambió su precio objetivo de $115 a $84 para Merck & Co Inc.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Merck & Co (MRK)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Merck & Co, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Merck & Co se registró el julio 30, 2025, por lo que la próxima calificación estará disponible en torno al julio 30, 2026.
¿Es correcta la calificación de los analistas sobre Merck & Co (MRK)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Merck & Co (MRK) fue un mantuvo con un precio objetivo de $97.00 a $90.00. El precio actual al que cotiza Merck & Co (MRK) es de $84.06, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.